FFA
NBIX icon

Fairfield Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Fairfield Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$13.7K – 147
2024
Q4 		$13.7K Hold
100
– – ﹤0.01% 189
2024
Q3 		$11.5K Hold
100
– – ﹤0.01% 218
2024
Q2 		$13.8K Buy
+100
New +$13.7K ﹤0.01% 193
2023
Q4 		$13.2K Buy
+100
New +$11.5K 0.01% 222

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fairfield Financial Advisors's NBIX Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 100 shares — an estimated $13.7K sold.

Fairfield Financial Advisors first reported a position in NBIX in Q4 2023 and held it in 4 quarters. The position peaked at $13.8K in Q2 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 100 Neurocrine Biosciences shares in Q1 2025, an estimated $13.7K.
  • Fairfield Financial Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 4 quarters.
  • Fairfield Financial Advisors's Neurocrine Biosciences position peaked at $13.8K in Q2 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.